Chugai Pharmaceutical Co., Ltd. provided consolidated earnings guidance for full year of year ending December 31, 2022. For the year, the company expected Core revenues of JPY 1,150,000 million, core operating profit of JPY 440,000 million, Core net income of JPY 312,500 million, core earnings per share of JPY 190.00 per basic share.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4,936 JPY | +2.60% | +3.11% | -7.60% |
05:20am | Japan's Nikkei rises on US stocks, heavyweight chip shares | RE |
May. 23 | Tech stocks lift Japan's Nikkei on boost from Nvidia's robust outlook | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.60% | 49.99B | |
+48.39% | 765B | |
-6.13% | 354B | |
+20.61% | 331B | |
+10.00% | 299B | |
+18.87% | 248B | |
-1.96% | 219B | |
+11.11% | 216B | |
+5.80% | 164B | |
-2.50% | 162B |
- Stock Market
- Equities
- 4519 Stock
- News Chugai Pharmaceutical Co., Ltd
- Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for Full Year of Year Ending December 31, 2022